PUBLIC PORTAL

MEDICALLY REVIEWED

Pralsetinib: Targeted Therapies for RET-Fusion Positive NSCLC

Share on email
Share on print
Share on whatsapp

Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more . . .

Sign Up or Log In as a healthcare professional to read the full article

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading